[ad_1]
SHANGHAI (Reuters) – A vaccine scandal in China, which has prompted angry reactions from the world's largest drug market.
Shares in the Chinese Academy of Biomedical Sciences and the United States of America on Monday after Premier Li Keqiang slammed Changsheng Biotechnology for a new course.
Changsheng has been discovered to be a child of the world in China, China, China, China, China, China, China, China promote its vaccines globally.
While there were no known reports of people being harmed by the vaccine, the regulator ordered the production of this product.
The case has gone viral in China, where sensitivity over food and drug is extremely high after a scandal over the last decade. Sina Weibo on Monday is one of the most hotly discussed topics on microblogging.
Hashtag related to the case, which was taken over by censors.
"All of my friends are freaking out with this vaccine case," "It's a big issue with China's food and drug regulation," wrote Cheng Cheng Weibo.
"Yesterday it was milk powder, today vaccines What will it be tomorrow?" another wrote, referring to a major scandal in 2008 when several infants died after industrial chemical melamine was added to milk powder to raise protein levels.
Li calls for probe
First Li called for an immediate investigation into the Changsheng case in a statement posted on the government's website late on Sunday, urging severe punishment for those implicated. He added the public needed clear information.
"We will resolutely crack down on the law and endanger the lives of peoples, resolutely punish lawbreakers according to the law, and resolutely and severely criticize dereliction of duty in supervision," he said.
According to the China Food and Drug Administration, Changsheng fabricated production records and product inspection records, and arbitrarily changed process parameters and equipment, in "serious violations" of the law.
Changsheng apologized in a regulatory filing on Monday and said the suspension of its vaccine would hit its finances. It added some regional disease control agencies had suspended some of its other vaccines.
The firm said it was the risk of being investigated by China's securities regulator.
Changsheng shares, which resumed trading on Monday afternoon after being suspended in the morning, were down 10 percent. They have slumped 47 percent since mid July. The wider CSI 300 healthcare index was down about 5 percent.
Public health crisis
The Changsheng case is the latest in a slew of scandals that has plagued China's pharmaceutical industry in recent years.
A regulator in the northeastern province of Jilin, where Changsheng was based, revealed on Friday that the company had 252,600 substandard DPT vaccines to inoculate children against diphtheria, whooping cough and tetanus.
Another Wuhan Institute of Biological Products company was also involved in the DPT vaccine issue. Earlier, in 2016, Chinese police busted a gang for selling around $ 90 million worth of illegal vaccines on the black market.
Marina Cui – a 25-year-old mother from the southwestern Yunnan province whose five-month old child took a DPT vaccine last week – said the latest revelations had made her worried about the overall safety of vaccines.
"The recent fake vaccine scandal has really made me very scared," she said, adding that she wanted information about authorities, rather than people with little knowledge or expertise about stirring up parents' emotional concerns.
The country's official newspaper China Daily has changed its mind in the case of the Changsheng case.
The government wants to let the public know it "will punish any wrongdoers without mercy", the paper wrote in an editorial.
Xinhua ran an editorial calling for strict punishment for all violations and for regulators to tighten oversight of the industry.
The state-run Global Times also weighed in, saying the case had "sparked nationwide outrage, (and) could pose serious challenges for a domestic
Source link
